Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers′ disease

Ana Maria Martin-Moreno, David Reigada, Belen G. Ramirez, Raphael Mechoulam, Nadia Innamorato, Antonio Cuadrado and Maria L. de Ceballos
Molecular Pharmacology February 24, 2011, mol.111.071290; DOI: https://doi.org/10.1124/mol.111.071290
Ana Maria Martin-Moreno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Reigada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Belen G. Ramirez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphael Mechoulam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadia Innamorato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Cuadrado
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria L. de Ceballos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Microglial activation is an invariant feature of Alzheimer′s disease (AD). Interestingly cannabinoids are neuroprotective by preventing β-amyloid (Aβ) induced microglial activation both in vitro and in vivo. On the other hand, the phytocannabinoid cannabidiol (CBD) has shown anti-inflammatory properties in different paradigms. In the present study we compared the effects of CBD with those of other cannabinoids on microglial cell functions in vitro and on learning behaviour and cytokine expression following Aβ intraventricular administration to mice. CBD, WIN 55,212-2 (WIN), a mixed CB1/CB2 agonist, and JWH-133 (JWH), a CB2 selective agonist, concentration-dependently decreased ATP-induced (400 [micro]M) increase in intracellular calcium ([Ca2+]i) in cultured N13 microglial cells and in rat primary microglia. In contrast HU-308 (HU), another CB2 agonist, was without effect. Cannabinoid and adenosine A2A receptors may be involved in the CBD action. CBD and WIN-promoted primary microglia migration was blocked by CB1 and/or CB2 antagonists. JWH and HU-induced migration was blocked by a CB2 antagonist only. All the cannabinoids decreased LPS-induced nitrite generation, which was insensitive to cannabinoid antagonism. Finally both CBD and WIN, following subchronic administration for three weeks, were able to prevent learning of a spatial navigation task and cytokine gene expression in β-amyloid injected mice. In summary, CBD is able to modulate microglial cell function in vitro and induce beneficial effects in an in vivo model of AD. Given that CBD lacks psychoactivity it may represent a novel therapeutic approach for this neurologic disease.

  • Cannabinoid
  • Purinergic
  • Nitric oxide
  • Tumor necrosis factor
  • Received January 18, 2011.
  • Revision received February 11, 2011.
  • Accepted February 11, 2011.
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 103 (2)
Molecular Pharmacology
Vol. 103, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers′ disease
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers′ disease

Ana Maria Martin-Moreno, David Reigada, Belen G. Ramirez, Raphael Mechoulam, Nadia Innamorato, Antonio Cuadrado and Maria L. de Ceballos
Molecular Pharmacology February 24, 2011, mol.111.071290; DOI: https://doi.org/10.1124/mol.111.071290

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers′ disease

Ana Maria Martin-Moreno, David Reigada, Belen G. Ramirez, Raphael Mechoulam, Nadia Innamorato, Antonio Cuadrado and Maria L. de Ceballos
Molecular Pharmacology February 24, 2011, mol.111.071290; DOI: https://doi.org/10.1124/mol.111.071290
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics